Neuryl clonazepam 2 mg
Neuryl clonazepam 2 mg may have a porphyrogenic effect and should be used with care in patients with porphyria.
Effect of Neuryl on the Pharmacokinetics of Other Drugs:
Neuryl does not appear to alter the pharmacokinetics of phenytoin, carbamazepine, or phenobarbital. The effect of Neuryl on the metabolism of other drugs has not been investigated.
Effect of Other Drugs on the Pharmacokinetics of Neuryl:
Literature reports suggest that ranitidine, an agent that decreases stomach acidity, does not greatly alter Neuryl pharmacokinetics.
In a study in which the 2 mg Neuryl orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of Neuryl was 10% lower and the Cmax of Neuryl was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.
Fluoxetine does not affect the pharmacokinetics of Neuryl. Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce Neuryl metabolism, causing an approximately 30% decrease in plasma Neuryl levels. Although clinical studies have not been performed, based on the involvement of the cytochrome P-450 3A family in Neuryl metabolism, inhibitors of this enzyme system, notably oral antifungal agents, should be used cautiously in patients receiving Neuryl.
The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.